期刊文献+

重度慢性阻塞性肺疾病患者撤除吸入性糖皮质激素需谨慎

Randomised controlled trial Discontinuing inhaled steroids might not be safe in severe COPD cases
原文传递
导出
摘要 背景对于频繁急性加重的慢性阻塞性肺疾病(COPD)患者推荐联合应用长效支气管扩张剂(LAB)和吸入性糖皮质激素(ICS)治疗。迄今尚无足够效度的临床试验证实在两种LAB的基础上加用ICS对缓解急性加重有额外的临床获益。作者进行了一项随机、双盲的临床试验,旨在验证这一假说:即COPD患者只要维持使用噻托溴铵和沙美特罗两种LAB的联合治疗,撤除ICS不会增加急性加重的风险。
出处 《英国医学杂志中文版》 2015年第5期290-291,共2页 The BMJ Chinese Edition
  • 相关文献

参考文献6

  • 1Barnes NC, Qiu YS, Pavord IA, et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006;173:736-43.
  • 2Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease : a randomised controlled trial. Lancet 2003 ;361:449-56.
  • 3Calverley PMA, Anderson JAA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007 ;356:775-89.
  • 4Wouters EFM, Postma DS, Fokkens B. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 2005 ;60:480-7.
  • 5Choudhury AB, Dawson CM, Kilvington HE, et al. Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial. Respir Res 2007 ;8:93.
  • 6Suissa S, Dell'Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 2012 ;67 :957-63. Therapeutics/Prevention.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部